[Bronchial arterial infusion chemotherapy with or without radiotherapy for advanced lung cancer].
Forty-two patients with Stage III and IV advanced lung cancer received bronchial arterial infusion of Cyclophosphamide or Mitomycin in combination with Adriamycin and Cisplatin (CAP or MAP). Twenty-six patients were given radiotherapy too. Histologically, 16 had squamous cell carcinoma, 11 adenocarcinoma, 3 small cell anaplastic carcinoma and 1 un-classified cancer. Eleven were diagnosed by bronchial arterial radiography. The short-term results showed that complete response rate (CR) was 53.8% and partial response rate (PR) 38.5% in patients treated with combined chemotherapy and radiotherapy whereas in those treated with infusion chemotherapy, CR and PR were 0% and 81.3% respectively.
Huang
D P
DP
Hankou Air Force Hospital, PLA, Wuhan.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001981:Bronchial Arteries; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage
D003037:Cobalt Radioisotopes; D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin